Twist Biopharma, a division of Twist Bioscience, expects to leverage its antibody discovery and optimization platform to discover novel antibodies against specific targets of interest that will be engineered into Kriya's proprietary gene therapy technology platform for durable and targeted delivery, the company said.

No financial details of the agreement were disclosed.

Twist Bioscience, Eleven Therapeutics create replicon for antiviral development
Twist Bioscience and Eleven Therapeutics have created a replicon tool that could be used for studying viral genome replication and antiviral drug screening...

Twist Bioscience develops innovative enzymatic DNA synthesis process
Twist Bioscience has developed an innovative, low-cost, scarless, and scalable enzymatic DNA synthesis process. With these comprehensive capabilities...

Twist Bioscience launches 96-plex library prep kit
Twist Bioscience has released the Twist 96-Plex Library Prep Kit, a high-performance, cost-effective preparation kit for next-generation sequencing.

Twist Bioscience to acquire Abveris for $190M
Twist Bioscience has entered into an agreement to purchase Abveris, a private in vivo antibody discovery firm, for $190 million.

Twist launches exome panel for genomics research
Twist Bioscience has launched Exome 2.0, an exome panel for genomics research.